Health and Pharmaceutical Sector Round Up for Q2 of 2026: Key Developments and Outlook for Q3 2026

www.strenandblan.com
contact@strenandblan.com
@strenandblan

+234 (0)702 558 0053
3 Theophilus Orji Street, Off Fola Osibo Road, Lekki Phase 1, Lagos, Nigeria

20th July, 2026

Executive Summary

Q2 2026 was a consequential quarter for Nigeria's health and pharmaceutical sector. The period reflected a clear policy shift from broad reform statements to more concrete implementation measures in disease control systems, emergency medical response, maternal and newborn care, medicine safety, digital pharmacy regulation and public health surveillance.

The Federal Government advanced a new National Malaria Strategic Plan (2026–2030) aligned with the Health Sector Strategic Blueprint, Sector-Wide Approach (SWAp) and the WHO Global Technical Strategy. The plan targets a 50% reduction in malaria parasite prevalence and mortality from 2025 levels by 2030. Legislative momentum also increased, as the Senate passed a bill to establish a dedicated National Agency for Malaria Elimination, signaling a shift toward a more institutionalized and coordinated malaria governance framework.

Public health preparedness also featured prominently. The Federal Government, the European Union and the World Health Organization launched a €4.2 million initiative to strengthen selected public health institutes, improve data use and support outbreak detection and response. In parallel, the Ministry of Health heightened Ebola preparedness and border health measures, while confirming that there was no confirmed Ebola case in Nigeria at the time of the advisory.

Healthcare delivery reforms were also visible. The launch of 145 tricycle ambulances and the distribution of approximately US$6 million worth of Comprehensive Emergency Obstetric and Newborn Care equipment to about 252 facilities across 30 states point to a renewed emphasis on emergency response and maternal/newborn outcomes. These interventions also create opportunities for service providers, logistics partners, equipment suppliers, health technology companies and healthcare investors.

From a regulatory perspective, the Federal Government introduced the Electronic Pharmacy Regulations 2026 by the Pharmacy Council of Nigeria under the Federal Ministry of Health and Social Welfare. The regulations create a more structured framework for e-pharmacy operations, including licensing, prescription management, medicines supply and quality assurance, monitoring, consumer protection, and data privacy and security.

The quarter also confirmed the increasing convergence of health regulation, consumer protection and digital accountability. The Federal High Court in Abuja affirmed the Federal Competition and Consumer Protection Commission's (FCCPC) authority to investigate healthcare-related consumer complaints, expanding regulatory oversight into patient service delivery and introducing consumer protection law as a parallel enforcement layer in the health sector. This development increases the need for healthcare providers to strengthen complaint handling, patient communication, pricing transparency, clinical documentation and regulatory response systems.

Overall, Q3 2026 is expected to be a transition period in which policy and regulatory announcements begin to move into implementation, licensing, compliance monitoring and enforcement. Operators in the health, pharmaceutical, digital health, diagnostic, telemedicine, e-pharmacy and healthcare logistics spaces should treat the quarter as a compliance-readiness window.

Table of Contents

Notable Developments in the Health Sector in Q2 2026

Federal Government Develops New National Malaria Strategic Plan, 2026-2030

The Federal Government has developed a new, robust National Malaria Strategic Plan, 2026-2030, in a proactive measure to reshape the response to malaria, despite its prevalence declining from 42% in 2010 to 15% in 2025. The Honorable Minister of State for Health and Social Welfare, Dr Iziaq Adekunle Salako, disclosed this development in his Keynote address as part of activities marking the commemoration of 2026 World Malaria Day, held in Abuja.[1]

This National Malaria Strategic Plan aligns with the National Health Sector Strategic Blueprint (HSSB), the Sector-Wide Approach (SWAp), and the WHO Global Technical Strategy (GTS) and aims to reduce malaria parasite prevalence and mortality by 50% from 2025 levels by 2030. With this strategic plan, the Ministry has long established the Advisory on Malaria Elimination in Nigeria, AMEN, bringing together a distinguished council of global experts to provide technical support, evidence-based guidance, and strategic direction for a more effective path toward a malaria-free Nigeria.

[1] Link <accessed on 7 June 2026>

FG, EU, WHO Partner To Strengthen Public Health Institutes with €4.2 Million

In Q2 2026, the Federal Government, the European Union and the World Health Organization partnered to Strengthen Public Health Institutes with €4.2 million. This initiative is fully aligned with the Renewed Hope Agenda of the current administration of His Excellency, President Bola Ahmed Tinubu GCFR, who recognizes health as central to national development and prosperity. The Honourable Minister of State for Health and Social Welfare, Dr Iziaq Adekunle Salako described that given the breakdown of health infrastructure owned by government at all levels, which includes over 30,000 primary healthcare centres, 4,000 secondary health facilities and over 200 tertiary health institutions, he reaffirmed that they are essential part of Nigeria's health system but are not enough to deliver health if strategies for coordination, prevention, early warning and prompt response to outbreaks are not put in place.

The €4.2 million initiative funded by the European Union and jointly implemented by the WHO and the Federal Government through the Health Ministry is aimed at helping strengthen core functions of selected public health institutes to detect outbreaks early, share information faster and reduce the negative impact of poor health outcomes across the country.[2]

[2] Link <accessed on 7 June 2026>

Nigeria Launches Emergency Medical Assets Nationwide

145 Tricycle ambulances are now operational to enhance emergency medical response in Nigeria. In Q2 of 2026, President Bola Ahmed Tinubu launched 145 tricycle ambulances aimed at improving emergency healthcare services across the country. Also, the Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, said the projects represented measurable progress towards achieving Universal Health Coverage by 2030 under the Nigeria Health Sector Renewal Investment Initiative.

In like manner, the Permanent Secretary, Federal Ministry of Health and Social Welfare, Daju Kachollom, announced that the ambulances would be deployed to primary healthcare centres, especially in rural areas, with trained drivers and health workers attached to ensure rapid response.[3]

[3] Link <accessed on 7 June 2026>

Federal Government Distributes $6m Maternal, Newborn Care Equipment to Health Facilities

The Federal Government has commenced the distribution of $6 million worth of Comprehensive Emergency Obstetric and Newborn Care (CEmONC) equipment to about 252 health facilities across 30 states in a renewed bid to crash maternal and newborn deaths in the country. A breakdown of the amount showed that each of the 30 benefiting states will receive CEmONC equipment valued at $200,000. This equipment package was tailored to the specific needs identified by states, ranging from oxygen concentrators and pharmaceutical-grade refrigerators to incubators and baby warmers.[4] This equipment serves as a significant milestone in strengthening Nigeria's health system and reducing financial hardship associated with maternal healthcare.

[4] Link <accessed on 7 June 2026>

FG Strengthens Pharmaceutical Industry to Boost Medicine Security

In Q2 2026, the Federal Government intensified efforts to strengthen Nigeria's pharmaceutical industry by providing technical support to local manufacturers to enhance medicine security and global competitiveness. The initiative, implemented through the National Institute of Pharmaceutical Research and Development (NIPRD) in collaboration with the National Malaria Elimination Programme and supported by the World Bank, aims to help indigenous firms achieve World Health Organisation (WHO) prequalification for medicines.

The intervention focuses on building local manufacturing capacity, improving compliance with international standards, and positioning Nigerian companies to participate in global procurement markets. It has led to measurable progress, including improved technical capacity among participating firms and the closing of key production gaps. The Federal Government emphasised that strengthening local pharmaceutical production is critical to reducing dependence on imports, ensuring equitable access to essential medicines, and advancing national health security.[5]

[5] Link <accessed on 8 June 2026>

Legal And Regulatory Updates

The Second quarter of 2026 witnessed several landmark policy and regulatory developments. Key updates included the introduction of electronic pharmacy regulations and updated national clinical protocols for obstetric and newborn care. The judiciary also reinforced regulatory oversight by affirming the FCCPC's authority to investigate patient complaints arising from healthcare services.

In addition, public health preparedness was heightened through improved pharmacovigilance systems and strengthened national surveillance measures against Ebola. The following is a summary of the most significant actions.

Federal Government Launches the Electronic Pharmacy Regulations 2026

Another interesting development in the second quarter of 2026 is with regard to the launch of the Electronic Pharmacy (e-pharmacy) Regulations, 2026. In April 2026, the Federal Government officially launched the Electronic Pharmacy Regulations 2026 under the Federal Ministry of Health and Social Welfare and the Pharmacy Council of Nigeria (PCN). The Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, disclosed that the Regulation is a clear vision to establish a safe, accessible, and fully regulated national e-pharmacy ecosystem that leverages digital technology to improve health outcomes. He enumerated the facets of digital pharmacy operations to include registration and licensing, prescription management, medicines supply and quality assurance, data privacy and security, monitoring and compliance, and consumer protection.

Elaborating more on the regulations, these provisions apply to all stakeholders in the e-pharmacy ecosystem: operators, licensed pharmacists, healthcare providers, regulators, and consumers.[6]

The Electronic Pharmacy Regulation, 2026, is expected to improve medicine traceability, strengthen the prescription regime and expand safe pharmaceutical access for both underserved areas and urban centres.[7]. It will also help to strengthen oversight, improve medicine safety and regulate Nigeria's fast-growing digital pharmaceutical market.[8]

[6] Link <accessed on 7 June 2026>

[7] Link <accessed on 7 June 2026>

[8] Link <accessed on 7 June 2026>

The Federal High Court, Abuja, Affirms FCCPC Authority to Investigate Patient Complaints Arising from Healthcare Services

In April 2026, the Federal High Court in Abuja confirmed that the FCCPC can investigate patient complaints against healthcare providers, including allegations of medical negligence. The judgment was delivered by Justice Emeka Nwite of the Abuja Federal High Court on April 15, following a suit (FHC/ABJ/CS/1019/2021) filed by Life Bridge Medical Diagnostic Centre Ltd challenging the powers of FCCPC to investigate complaints involving healthcare services rendered to consumers.[9]

The Court held that healthcare providers operating as commercial entities fall within the scope of the Federal Competition and Consumer Protection Act 2018, and are therefore subject to consumer protection oversight. The judgment carries implications for healthcare providers, diagnostic centres, and medical facilities. Stakeholders should now review complaint-handling processes, strengthen service quality standards, and align internal compliance frameworks with consumer protection requirements to mitigate regulatory and litigation risks.[10]

[9] Link <accessed on 7 June 2026>

[10] Link <accessed on 7 June 2026>

Federal Ministry of Health Introduces Updated National Obstetric and Newborn Clinical Protocols and Guidelines

In Q2 2026, the Federal Ministry of Health introduced updated national obstetric and newborn clinical protocols and guidelines. The Federal Government has emphasized the need for concrete actions to ensure that health facilities deliver quality care to safeguard the lives of mothers and newborns across the country. These include the revised Antenatal Care (ANC) Guidelines, the Obstetrics Clinical and Newborn Service Protocol, Life-Saving Skills (LSS) and Expanded LSS training packages, Maternal and Newborn Health Commodity Reporting Tools, the Maternal and Newborn Product Introduction Plan, and the MAMII Comprehensive Guide. The updated National Obstetric and Newborn Clinical Protocols and Guidelines are committed to strengthening health systems, improving the quality of care, and ensuring that no woman or newborn is left behind.[11]

[11] Link <accessed on 7 June 2026>

NAFDAC Launches Improved Med Safety App to Strengthen Reporting of Adverse Drug Reactions in Nigeria

The National Agency for Food and Drug Administration and Control (NAFDAC) has officially launched the improved Med Safety App, a digital platform designed to empower healthcare professionals and members of the public to report suspected Substandard and Falsified (SF) medical products as well as Adverse Drug Reactions (ADR) quickly, easily, and securely. The launch marks another significant milestone in NAFDAC's ongoing efforts to strengthen post-marketing surveillance, enhance public participation in medicine safety monitoring, and protect Nigerians from the dangers posed by poor-quality, and falsified medical products. It should be noted that substandard and falsified medical products remain a major public health challenge globally and in Nigeria, contributing to treatment failure, prolonged illness, antimicrobial resistance, disability, and preventable deaths.

The fight against substandard and falsified medical products and adverse drug reactions requires a whole-of-society approach. Through the improved Med Safety App, every Nigerian now has a simple and effective tool to contribute to safeguarding public health by reporting suspicious medical products and adverse drug reactions directly to NAFDAC.[12]

[12] Link <accessed on 7 June 2026>

Federal Government Heightens Ebola Preparedness, Strengthens National Surveillance and Health Measures

The Federal Ministry of Health and Social Welfare has intensified national preparedness and response measures to safeguard Nigeria against the possible introduction of the Bundibugyo ebolavirus disease (BEBOV), currently reported in parts of the East and Central African region. It should be noted that there are presently no confirmed cases of Ebola Virus disease in Nigeria; however, in line with the Federal Government's commitment to strengthening national health security and preventing cross-border disease transmission, heightened preparedness measures have been activated nationwide.[13]

[13] Link <accessed on 7 June 2026>

Policy and Governance Developments

Senate Passes Bill to Establish National Agency for Malaria Elimination



In Q2 2026, the Senate passed the National Agency for Malaria Elimination Bill. Sponsoring the legislation, Senator Ned Nwoko (Delta North) declared the bill's passage a historic turning point, asserting that Nigeria is finally ready to transition from merely managing malaria to eliminating it. Nwoko maintained that Nigeria could replicate the success recorded by other nations if it invested more in aggressive environmental management and fumigation to target mosquitoes and breeding sites; advanced research, surveillance, and data collection; Widespread public awareness campaigns and grassroots elimination strategies executed via federal, state, and local government partnerships. If enacted, the National Agency for Malaria Elimination will stand as one of the most ambitious public health initiatives in Nigeria's recent history, positioning the nation as a leader in the continent-wide campaign to eradicate malaria. The bill, which successfully scaled its third reading, seeks to establish a dedicated, data-driven institution tasked with coordinating a comprehensive national response to the disease.[14]

[14] Link <accessed on 7 June 2026>

President Tinubu Approves ₦17 Billion Community-Led Development Fund Across 8,804 Wards, Upgrades Zaria Health Institution

The Federal Government has approved the establishment of a Community-Based National Social Action Fund Taskforce to drive grassroots development and accelerate socio-economic improvements across Nigeria's 8,804 wards. The initiative, approved by President Bola Ahmed Tinubu, GCFR, will deploy community-driven interventions tailored to local needs, with each ward engaging a verified community-based entity, organisation, or association to implement priority projects. The approval builds on earlier reforms, including the creation of the Social Action Fund (SAF) in September 2023 and the Community-Based Procurement Platform approved in January 2026, designed to simplify access for community organizations to deliver projects of up to ₦50 million. In line with this, the Federal Ministry of Finance and the Office of the Accountant-General of the Federation have been directed to release the sum of ₦17 billion into a ring-fenced special intervention account to support implementation, monitoring, communication, and accountability. The Institute will function as a multidisciplinary hub for public health training, research, and workforce development, expanding access to advanced learning and strengthening the country's readiness to manage infectious disease threats.

Senate Passes the National Health Act Amendment Bill, 2026

The Senate passed the National Health Act (Amendment) Bill as part of broader efforts to strengthen Nigeria's healthcare system and improve service delivery nationwide. The amendment primarily seeks to enhance health financing and system coordination by increasing the Basic Health Care Provision Fund (BHCPF) from one per cent to two percent of the Consolidated Revenue Fund, thereby boosting resources available for primary healthcare services. The bill also introduces reforms aimed at improving the structure, coordination, and effectiveness of healthcare delivery, particularly at the secondary and tertiary levels, while reinforcing accountability in the use of health resources. Key provisions further support expanded access to essential health services, sustainable funding for immunization and other priority programmes, and strengthened infrastructure, workforce capacity, and availability of medicines, especially for vulnerable and underserved populations.

The Federal Government has emphasized that the passage of the amendment represents a significant step toward achieving universal health coverage, reducing out-of-pocket health expenses, and ensuring equitable access to quality healthcare services. Overall, the National Health Amendment Bill reflects a renewed commitment to building a resilient, well-funded, and inclusive health system that improves outcomes for all Nigerians.[15]

[15] Link <accessed on 8 June 2026>

Outlook: What To Expect In Q3 2026

Based on the Q2 health and pharmaceutical developments, Q3 2026 is likely to shift from policy announcement and rollout to implementation, enforcement, and regulatory tightening across Nigeria's health and pharmaceutical sector.

The most consequential thread will continue to be the malaria elimination reform agenda, which by Q3 will no longer be defined by strategic documentation or legislative approval alone, but by the practical question of institutional readiness. The National Malaria Strategic Plan (2026–2030), combined with the Senate's passage of the bill establishing a dedicated malaria elimination agency, effectively creates a dual-track system: one policy-driven and the other institution-building.

Running parallel to this is the emerging enforcement phase of the Electronic Pharmacy Regulations 2026, which in Q3 is likely to become one of the most visible regulatory pressure points in the sector. Having moved beyond issuance, the real test will be licensing uptake, compliance audits, and enforcement against unregistered digital pharmacies.

The transition of the Electronic Pharmacy Regulations 2026 into active enforcement introduces a new compliance threshold for participants in Nigeria's pharmaceutical value chain, particularly e-pharmacy platforms, online marketplaces, logistics providers, and licensed pharmacists operating digital channels. Businesses that previously operated in loosely regulated or informal digital environments will now face increased scrutiny around licensing status, prescription validation processes, storage and distribution standards, and data protection obligations.

This is likely to result in short-term operational disruptions, including platform audits, potential shutdowns of non-compliant services, increased compliance costs, and reputational risks for defaulting operators. At the same time, the regulation creates a structured and more credible marketplace, which may benefit compliant and well-capitalized players through improved consumer trust, reduced counterfeit risks, and clearer competitive differentiation.

As a way of recommendation, businesses are advised to assess whether their operations fall within the scope of the Electronic Pharmacy Regulations 2026 and ensure they comply with the necessary licensing requirements of the Pharmacy Council of Nigeria (PCN), while strengthening internal compliance systems around prescription validation, pharmacist oversight, and medicine sourcing; they should also invest in secure digital infrastructure to support data protection and traceability, conduct due diligence on supply chains to ensure alignment with NAFDAC standards, restructure non-compliant operating models where necessary, and maintain proactive engagement with regulators to keep pace with evolving enforcement expectations.

At the same time, the Federal High Court's affirmation of FCCPC jurisdiction signals a fundamental shift in how healthcare services are regulated in Nigeria, effectively expanding oversight beyond clinical and technical regulators into the domain of consumer protection.

Healthcare providers, including hospitals, diagnostic centres, telemedicine platforms, and HMOs, are now exposed to a dual regulatory regime where service quality, pricing transparency, patient communication, and complaint resolution processes may trigger FCCPC investigations.

This development increases litigation and enforcement risk, particularly in cases involving allegations of negligence, misleading representations, unfair pricing, or inadequate disclosure. It also raises the likelihood of financial penalties, reputational damage, and compulsory operational reforms arising from consumer complaints, expected to begin translating into actual regulatory activity in Q3, moving the Commission from interpretive authority into practical enforcement.

As a way of recommendation, businesses are advised to implement effective complaint management systems to resolve patient issues promptly and avoid regulatory escalation, improve transparency in pricing and service delivery, conduct periodic legal and compliance reviews, train staff on consumer protection obligations, maintain proper records, and ensure adequate insurance coverage to mitigate potential regulatory investigations and fines.

On the regulatory front, NAFDAC's expansion of digital pharmacovigilance through the Med Safety App is likely to begin generating meaningful enforcement intelligence in Q3. However, the real issue will not be the existence of the reporting platform, but the regulatory system's capacity to convert data into timely enforcement action. Increased adverse drug reaction reporting will inevitably lead to more targeted recalls, warnings, and product withdrawals, particularly in high-risk therapeutic categories.

Taken together, Q3 2026 is likely to represent a transition quarter in which Nigeria's health sector begins to reveal the gap between regulatory ambition and implementation capacity. The reforms introduced in Q2 collectively point toward a more centralized, digitized, and enforcement-driven health governance model. However, the quarter ahead will determine whether these reforms consolidate into a coherent system or begin to fragment under the weight of institutional coordination challenges, uneven compliance, and the realities of subnational execution.

Conclusion

Q2 2026 confirmed that Nigeria's health and pharmaceutical sector is moving into a more structured, digitised and enforcement-conscious regulatory environment. The reforms and initiatives recorded during the quarter touch almost every part of the sector: public health surveillance, emergency response, maternal and newborn care, digital pharmacy, medicine safety, local manufacturing, consumer protection and health financing.

For businesses, the message is clear. Regulatory compliance is becoming an operational requirement and a competitive differentiator. Organisations that build strong governance, reliable documentation, patient-focused systems, product-quality controls and regulator-ready compliance frameworks will be better positioned to manage risk and take advantage of new opportunities in the sector.

The outlook for Q3 2026 is therefore not merely about new announcements. It is about implementation readiness, regulatory engagement and the ability of health-sector participants to demonstrate that their operations are safe, accountable, compliant and capable of supporting Nigeria's broader health-system renewal agenda.

For further enquiries, reach out to **contact@strenandblan.com**

About **Stren & Blan Partners**

Stren & Blan Partners is an innovative and dynamic Law Firm with a compelling blend of experienced lawyers and energetic talents. We are focused on providing solutions to our client's business problems and adding value to their businesses and commercial endeavours. This underpins our ethos as everything we do flows from these underlying principles.

Stren & Blan Partners is a full-service commercial Law Firm that provides legal services to diverse local and multinational corporations. We have developed a clear vision for anticipating our client's business needs and surpassing their expectations, and we do this with an uncompromising commitment to Client service and legal excellence.

The **Authors**





Francisca Igboanugo
Team Lead

Omolola Ambrose
Senior Associate

Emmanuel Ughanze
Associate

Oluchukwu Nwakor
Associate

Obinna Odikaesieme
Associate

SB
STREN & BLAN
PARTNERS